Platin-DRP® achieved major clinical milestones in 2025, showing predictive value for survival in lung and breast cancer. Financially, the group reported a net loss and strong equity ratio, with recent capital raises expected to fund operations through Q1 2027.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.